Kornimate/medical-research-clean huggingface dataset:
evaluation of planned conservative surgical management of placenta accreta spectrum in women's health center, assiut university hospital

Conditions: Placenta Accreta

Summary: in recent years, with the application of an abdominal artery balloon and the improvement of surgical techniques, efforts are made to preserve the uterus for patients pas. the aim of the study to evaluate conservative surgical management of placenta accreta spectrum in assiut university hospital regarding maternal and fetal outcomes.

placenta accreta spectrum disorder (pas) is a serious obstetric disorder that is characterized by low lying and deep penetration of the villi which are abnormally attached to the myometrium of the uterus. this obstructs its complete separation during the third stage of labor which induces continued bleeding and have potentially life- threatening for the mother. most commonly, it is a consequence of a partial or complete absence of the compact and spongy layer known as the decidua basalis, and mis-development of the fibrinoid nitabuch's layer which lies between the boundary zone of the thick endometrium and the cytotrophoblastic shell in the placenta. traditionally, caesarean hysterectomy at the time of delivery has been the preferred management strategy for placenta previa accreta. not only does this approach preclude future fertility, but it is also a procedure synonymous with significant perioperative risks. for women who wish to conserve their reproductive function, other treatment options have been described. different methods have been employed to manage the pa, ranging from uterine conservation, which involves leaving the placenta in situ, to conventional hysterectomy. classical cesarean sections (c- sections) prevent the excessive bleeding by leaving the adherent placenta in situ and by adopting strategic planning with a comprehensive analysis that aids the reduction in maternal morbidity and mortality rates.

Eligibility criteria:
inclusion criteria: 1. pregnant women with history of previous caesarean section. 2. age above 18 years. 3. gestational age above 28 weeks. 4. u/s signs suggestive of placenta previa accreta. 5. confirmed diagnosis of placenta previa accreta spectrum disorder by 3 d u/s, doppler or mri if needed. exclusion criteria: 1. gestational age less 28 weeks. 2. age less than 18 years. 3. patients with known bleeding disorders. 4. multiple pregnancy. 5. other pathology (fibroid, ....................). 6. patients with placental separation.

Keywords: planned conservative surgical managemen
efficacy and safety of adding azarga to prostaglandin monotherapy

Conditions: Glaucoma

Summary: the purpose of this study is to assess the safety and efficacy of adding azarga in glaucoma patients with uncontrolled intraocular pressure (iop), currently on prostaglandin monotherapy.


Eligibility criteria:
inclusion criteria: * sign informed consent. * 21 years of age or older. * able to follow instructions and willing to attend required study visits. * clinical diagnosis of ocular hypertension, primary open-angle, or pigment dispersion glaucoma in at least one eye (qualifying eye). * intra-ocular pressure (iop) considered to be safe in both eyes in such a way that should assure clinical stability of vision and the optic nerve throughout the trial. * must have best corrected visual acuity of 6/60 (6/60 snellen, 1.0 logmar) or better in each eye. * other protocol-defined inclusion criteria may apply. exclusion criteria: * presence of other primary or secondary glaucomas not listed in inclusion criterion. * presence of corneal dystrophies. * concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. * intraocular conventional surgery or laser surgery in qualifying eye(s) less than three months prior to visit 1. * risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's best judgment. * women of childbearing potential not using reliable means of birth control. * women who are pregnant or lactating. * participation in any other investigational study within 30 days prior to visit 1. * current or anticipated use of systemic corticosteroids, by any route except inhaled, for greater than two weeks during the trial. * severe allergic rhinitis * history of ocular herpes simplex. * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma iop azarga
magnetic resonance angiography for peripheral arterial disease (pad)

Conditions: Peripheral Arterial Disease (PAD)

Summary: the purpose of this study is to compare the difference between two magnetic resonance imaging (mri) techniques for visualizing arteries. the study hypothesizes that one method that relies upon imaging flowing blood in the pelvic and leg arteries will not be as accurate or efficient as injecting a safe imaging agent to change the appearance of the blood on the mri. both methods will be compared with digital subtraction angiography (dsa).


Eligibility criteria:
inclusion criteria: * subjects with symptoms of pad * scheduled for dsa exclusion criteria: * critical leg ischemia manifested by ulcers, gangrene or leg amputation * laboratory evidence of iron overload, liver disease, pregnancy * history of allergy to or recent exposure to radiocontrast, gadolinium chelates, or intravenous iron therapy * clinical concerns about co-morbidities, subject suitability

Keywords: peripheral arterial disease (pad); magnetic resonance angiography (mra); magnetic resonance imaging (mri), imaging agent or biomarker
effects of oxymizer pendant cannula versus conventional nasal cannula during endurance shuttle walk tests in hypoxemic patients with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis; Hypoxemia

Summary: aim of this study is to investigate the effects of an oxymizer pendant nasal cannula in hypoxemic patients with idiopathic pulmonary fibrosis during walking.

patients will be recruited during an inpatient pulmonary rehabilitation program. they will perform three shuttle walk tests on three consecutive days (see below). while performing those tests, the patient's prescribed oxygen flow rate is applicated either through the conventional nasal cannula (cnc) or the oxymizer.on the first day, patients perform an incremental shuttle walk test to determine maximum walking speed using a conventional nasal cannula. on two consecutive days, patients will perform two endurance shuttle walk tests at 85% of the maximum incremental shuttle walk test speed. supplemental oxygen will be provided via nasal cannula at the prescribed oxygen flow rate. patients will be randomly assigned to perform one test with the oxymizer and the other one with a conventional nasal cannula.

Eligibility criteria:
inclusion criteria: * firmed diagnosis of idiopathic pulmonary fibrosis * indication for supplemental oxygen therapy during exercise * referred to an inpatient rehabilitation program at the schön klinik berchtesgadener land exclusion criteria: * cardiovascular diseases that influence the patient's physical performance * orthopedic comorbidities that prevent the patient from performing an incremental or endurance shuttle walk test * carbon dioxide pressure above 45 mmhg at rest and ambient air

Keywords: ipf oxymizer oxygen conserving device pulmonary disease
ephedrine versus ondansetron during cesarean delivery

Conditions: Spinal Induced Hypotension

Summary: more than 30% of the patients receiving spinal anesthesia develop hypotension. hypotension developed during cesarean section (c/s) under spinal anesthesia may jeopardize uteroplacental circulation leading to fetal compromise and even fetal death. the effect of prophylactic ondansetron on blood pressure after spinal anesthesia has not been compared in a clinical trial with that of a vasoconstrictor. the investigators will compare ephedrine and ondansetron for the prevention of maternal hypotension after spinal anesthesia for elective cesarean delivery.

some vasopressive drugs including ephedrine and phenylephrine have been widely used to prevent maternal hypotension. although ephedrine has mixed a-adrenoceptor activity , it maintains arterial pressure mainly by increases in cardiac output and heart rate as a result of its predominant activity on β1-adrenoceptors. it has been demonstrated that ondansetron preloading with crystalloid infusion reduces maternal hypotension in parturient women undergoing cesarean delivery. ondansetron has been widely used in the clinic to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. ondansetron has been proven as a well-tolerated drug, but the most common side effects of ondansetron include headache, constipation, diarrhea, asthenia, and somnolence.

Eligibility criteria:
inclusion criteria: * age \>18, \<40 years; * american society of anesthesiologists physical status i or ii; * term pregnancy * singleton pregnancy; * elective cesarean delivery under spinal anesthesia exclusion criteria: * patients with a history of diabetes mellitus other than gestational diabetes, * hypertension, * body mass index \>40 kg/m2, * complicated pregnancy, allergy to study drugs, * long qt syndrome, * contraindication to spinal anesthesia * patients who required general anesthesia were withdrawn from the study.

Keywords: cesarean section bezold-jarisch reflex ondansetron
evaluating evidenced based options for ptsd treatment

Conditions: PTSD - Post Traumatic Stress Disorder

Summary: this study will look at: how practical it is to offer another round of proven therapy. how effective different therapy options are for people who didn't respond to the first treatment. the goal is to improve personalized care by: identifying factors that might predict how someone will respond to a second treatment. creating a simple tool to spot people who might not respond to treatment early, so they can start a different option sooner. the findings will help improve ptsd care by offering better follow-up treatments and matching patients with the approach that works best for them.


Eligibility criteria:
inclusion criteria: * are 18 years or older * are fluent in english * have experienced a criterion a traumatic event during their lifetime * have a ptsd diagnosis verified via the clinician administered ptsd scale for dsm-5 * are interested in receiving evidence-based treatment for ptsd and able to attend 10 therapy sessions over the course of 2 weeks (10 days) and could possibly attend another 10 sessions of a subsequent treatment (additional cpt sessions, pe, or stair) * are willing and able to complete self-report measures and clinician-rated assessments at multiple timepoints over the course of the study exclusion criteria: * the index traumatic event occurred in the past month * they are currently suicidal or homicidal (i.e., current plan and imminent intent) * they have unmanaged psychosis or mania * they have not been on a stable dose of psychotropic medication for at least one month at the time of the baseline assessment * they have completed an evidence-based cognitive behavioral ptsd treatment in the past three months or are currently engaged in an evidence-based ptsd treatment (cpt, pe) * they have an intellectual disability or significant cognitive impairment that would prevent them from engaging in treatment * they have a serious or unstable medical illness or instability for which hospitalization may be likely within the next year * they have an active substance use disorder (within the past three months) that would require immediate medical observation if substance was abruptly discontinued * they are involved with current legal actions related to their index trauma * they have a visual or auditory impairment that would prevent them from fully participating in study activities * they, at the time of consent, appear to have extenuating life circumstances (i.e., unstable housing, no internet access, etc.) which, in the judgement of the study team, could affect the ability to deliver interventions with fidelity

Keywords: ptsd treatment
protopic adherence and efficacy in korean eczema patient

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine whether the dosage of 0.1% tacrolimus ointment applied on unit area of eczema influence the efficacy of treatment.


Eligibility criteria:
inclusion criteria: * at least 19 years of age with a diagnosis of atopic dermatitis * treated with protopic 0.1% ointment exclusion criteria: * treated with other medication or topical agent * skin lesion on the scalp or hand and foot * pregnant women/lactating women
effect of choline fenofibrate (slv348) on macular edema

Conditions: Diabetic Macular Edema

Summary: the purpose of this study is to evaluate the effect of choline fenofibrate on the regression of macular edema in eyes of subjects with type 2 diabetes mellitus (t2dm) presenting with diabetic macular edema (dme)


Eligibility criteria:
inclusion criteria * with dme in at least one eye of the subject and this eye presenting with macula thickness ≥ 300 µm on oct examination at baseline in at least one of the 5 following zones: center zone, or superior inner zone, or nasal inner zone, or inferior inner zone, or temporal inner zone, confirmed after central reading of the oct; * when laser treatment can be safely postponed by up to at least 3 months; * with established t2dm and hba1c \< 10%; * with systolic blood pressure (sbp) or diastolic blood pressure (dbp) \< 160/90 mmhg; * with documented elevated triglyceride levels (tg \>=150 mg/dl \[1.70 mmol/l\]) at the screening visit or in the previous 3 months. exclusion criteria * previous laser photocoagulation; * eye retinal thickening results from epiretinal membranes or vitreomacular traction; glaucoma; * poor visual acuity: visual acuity of 20/800

Keywords: diabetic macular edema oct
standard lipid therapy vs ivfe minimization for prevention of pnald

Conditions: Cholestasis

Summary: parenteral nutrition-associated cholestasis (pnac) and liver disease (pnald) are associated with significant morbidity and mortality in neonates and is felt to be exacerbated by soybean-based lipid emulsions. much research is currently being directed at identifying ways to reduce this risk. reduction of the dose of soybean-based lipid given as a component of parenteral nutrition is one possible strategy. in this study we will compare standard dosing of soybean-based lipid (up to 3/kg/day) with a minimized dose (1 g/kg/day) and evaluate for the development of cholestasis and adequate growth between the two groups. longterm followup will include an assessment of neurodevelopmental outcomes at 12 and 24 months of age. funding source - fda oopd


Eligibility criteria:
inclusion criteria: * neonates and infants who are at least 28 weeks corrected gestational age at the time of enrollment who are parenteral nutrition (pn) naive * current direct bilirubin \<2 mg/dl * any of the following conditions: * meconium ileus and peritonitis * gastroschisis * omphalocele \>4cm or with liver herniated outside of the abdominal cavity * necrotizing enterocolitis requiring surgical intervention * volvulus * intestinal atresia with \>50% bowel loss exclusion criteria: * weight \<1 kg * metabolic pathway defect which is associated with liver dysfunction in the neonatal period, including: hereditary fructose intolerance, galactosemia due to transferase deficiency and neonatal tyrosinemia, and/or disorder of lipid metabolism * hepatic insufficiency as documented by either a biopsy with cirrhosis and/or marked aberration in synthetic function * renal failure * primary or secondary liver disease, regardless of liver function (includes hepatitis) * use of extracorporeal membrane oxygenation (ecmo) * suspected congenital obstruction of the hepatobiliary tree * documented active infection which may be communicable, including infections hepatitis or hiv * previous receipt of choleretic agents * currently receiving phenobarbital or other barbiturates * history of pnac * direct bilirubin \>=2 mg/dl at time of enrollment * congenital or acquired anomaly which will require major cardiovascular surgery * major congenital or chromosomal anomaly * hypoxic ischemic encephalopathy * congenital defect of the brain * major seizure disorder
drug use investigation of zyvox (linezolid) (regulatory post marketing commitment plan)

Conditions: Staphylococcal Infections

Summary: drug use investigation of zyvox for patients with methicillin-resistant staphylococcus aureus (mrsa) infection disease. the objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the package insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

all the patients whom an investigator prescribes the first linezolid should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: * patients need to be administered linezolid in order to be enrolled in the surveillance. exclusion criteria: * patients not administered linezolid.
build-up of action representation in autism spectrum disorders

Conditions: Healthy; Autism Spectrum Disorder

Summary: autistic spectrum disorders (asd) are highly debilitating developmental syndromes which core feature is social and communications disorders. motor skill impairments are frequently described in autism, but few studies have addressed the question of their origin and their specificity. furthermore, it is not clear whether motor problems encountered in autism are related to dyspraxia, or if they present with specific features. this project aims at deciphering the origin of motor problems encountered by children who grow-up with autism in order to propose early interventions that could influence the other developmental trajectories, such as the social one. brain dynamics during sensori-motor learning is explored by applying magnetoencephalography (meg) during the bimanual load-lifting paradigm. different motor processes namely: proprioceptive monitoring, use and update of a sensori-motor representation, anticipatory executive control will be correlated to brain oscillation modulation, both topographically and temporally. two groups of children (aged between 7 and 12) are compared: a group of children with asd and a control group of typically developing children.


Eligibility criteria:
inclusion criteria: * control group: children aged between 7 and 12 * case group: children aged between 7 and 12 with a diagnostic of autism spectrum disorders exclusion criteria: * control group: presence of a neurological pathology, mental retardation or language and motor developmental delay * case group: presence of a neurological pathology, mental retardation

Keywords: autism sensori-motor learning development neuroimaging
non-surgical mechanical debridement with or without full-mouth disinfection in the treatment of peri-implant mucositis

Conditions: Peri-implant Mucositis

Summary: to evaluate the naturally occurring peri-implant mucositis (pm) treatment by means of non-surgical sub-marginal peri-implant instrumentation (nspi) with or without full-mouth disinfection approach (fmd). specifically, the primary outcome of the present study compared the efficacy of nspi and full-mouth disinfection (fmd) with respect to nspi and placebo in the treatment of pm at 6 months follow-up. the secondary outcome evaluated the influence of possible predictors on the bop changes among all follow-up sessions.

fifty-six patients with 85 implants affected by pm were randomly assigned to test (nsmd+fmd) or control procedures (nsmd + placebo). at baseline, 1, 3, 6 months, full-mouth plaque score (fmps), full-mouth bleeding score (fmbs), probing depth (pd), bleeding on probing (bop), modified gingival index (mgi), and modified plaque index (mpli) were assessed. furthermore, the proportions of aggregatibacter actynomycencomitans, porphyromonas gingivalis, tannerella forsythia and treponema denticola were also recorded. the bop reduction was set as a primary outcome and the patient was considered statistical unit. data were analysed to assess bop reduction at a 6-month follow-up and to identify significant predictors of implant-site bop through mixed generalized linear regression.

Eligibility criteria:
inclusion criteria: * age ≥18 years old; * implants with smooth necks supporting cemented or screw-retained single-unit crowns with at least one bop-positive site (berglundh et al., 2018), * implants placed in both maxilla and mandible * patients with gingivitis or treated periodontitis with the absence of residual pd ≥5 mm * presence at least of 2 mm of keratinized mucosa (kt) at implant sites exclusion criteria: * presence of systemic diseases; * pregnancy or lactating; * use of inflammatory drugs or antibiotics within 3 months prior to study recruitment; * implants with modified (i.e., micro-rough) necks; * interproximal open contacts between implant restoration and adjacent teeth; * peri-implantitis (berglundh et al., 2018)
collection of samples from subjects with various skin conditions and healthy volunteers

Conditions: Acne; Atopic Dermatitis; Chronic Hand Eczema; Hidradenitis Suppurativa; Plaque Psoriasis; Palmoplantar Pustulosis

Summary: the purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.

this study is being conducted to collect samples from subjects with various skin conditions as well as healthy volunteers. collected samples may be used for different analyses including, but not limited to, biomarker and gene expression analyses.

Eligibility criteria:
inclusion criteria: all subjects: 1. subject is willing to participate and is capable of giving informed consent. note: consent must be obtained prior to any study-related procedures. 2. subject must be willing to comply with all study procedures and must be available for the duration of the study. healthy volunteers: 3. male or female subject aged 18 years or older, at the time of consent. 4. subject is in good general health, according to the investigator's judgment. subjects with acne: 5. male or female subject aged 18 to 45 years old, inclusive, at the time of consent. subjects with ad: 6. male or female subject aged 18 years or older, at the time of consent. 7. subject has clinically confirmed diagnosis of active ad, according to hanifin and rajka criteria. subjects with che: 8. male or female subject aged 18 years or older, at the time of consent. 9. subject has at least a 6-month history of che before screening (information obtained from medical chart or subject's physician, or directly from the subject). subjects with hs: 10. male or female subject aged 18 years or older, at the time of consent. 11. subject has a clinically confirmed diagnosis of active hs with a disease duration of ≥ 6 months before screening as determined by the investigator through subject interview and/or review of the medical history. subjects with ppp: 12. male or female subject aged 18 years or older at the time of consent. 13. subject has at least a 6-month history of ppp as defined by the presence of pustules on palms and/or soles, but without evidence of infection on palms and soles (information obtained from medical chart or subject's physician, or directly from the subject). subjects with psoriasis: 14. male or female subject aged 18 years or older, at the time of consent. exclusion criteria: all subjects: 1. subject is a female who is pregnant or who is planning to become pregnant during the study. 2. subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.